Evidence map›Paper›PMID 36059148›Full record

ArticleThe Journal of clinical endocrinology and metabolism2022

Aspirin Mediates Its Antitumoral Effect Through Inhibiting PTTG1 in Pituitary Adenoma.

Borbála Szabó, Kinga Németh, Katalin Mészáros, Lilla Krokker, István Likó, Éva Saskői, Krisztina Németh, Pál Tamás Szabó, Nikolette Szücs, Sándor Czirják and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical endocrinology and metabolism, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.8field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Journal of the Endocrine Society · 2026
    Article
  2. Review
  3. Article
  4. DNA Methylation in Pituitary Adenomas: A Scoping Review.International journal of molecular sciences · 2025
    Article
  5. Review
  6. Integrative Analysis of the Role ofCurrent issues in molecular biology · 2023
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 2 countries.

Borbála SzabóDepartment of Laboratory Medicine, Semmelweis University, H-1089 Budapest, Hungary.
Kinga NémethHereditary Tumours Research Group, Hungarian Academy of Sciences-Semmelweis University, H-1089 Budapest, Hungary.
Katalin MészárosHereditary Tumours Research Group, Hungarian Academy of Sciences-Semmelweis University, H-1089 Budapest, Hungary.
Lilla KrokkerDepartment of Laboratory Medicine, Semmelweis University, H-1089 Budapest, Hungary.
István LikóHereditary Tumours Research Group, Hungarian Academy of Sciences-Semmelweis University, H-1089 Budapest, Hungary.
Éva SaskőiDepartment of Molecular Genetics and the National Tumor Biology Laboratory, National Institute of Oncology, H-1122 Budapest, Hungary.
Krisztina NémethMS Metabolomics Research Group, Centre for Structural Study, Research Centre for Natural Sciences, Eötvös Loránd Research Network, H-1117 Budapest, Hungary.
Pál Tamás SzabóMS Metabolomics Research Group, Centre for Structural Study, Research Centre for Natural Sciences, Eötvös Loránd Research Network, H-1117 Budapest, Hungary.
Nikolette SzücsDepartment of Endocrinology, Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University, H-1083 Budapest, Hungary.
Sándor CzirjákNational Institute of Clinical Neurosciences, H-1145 Budapest, Hungary.
Gábor SzalókiDepartment of Pathology and Experimental Cancer Research, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary.
Attila PatócsDepartment of Laboratory Medicine, Semmelweis University, H-1089 Budapest, Hungary.
Henriett ButzDepartment of Laboratory Medicine, Semmelweis University, H-1089 Budapest, Hungary.ORCID 0000-0003-1664-409X
Semmelweis University · HUNational Institute of Oncology · HUOrszágos Idegsebészeti Tudományos Intézet · HUResearch Network (United States) · US

Funding

Bolyai Research FellowshipDevelopment and Innovation OfficeHungarian Academy of SciencesHungarian Scientific ResearchHungarian Thematic Excellence ProgrammeLaboratories Excellence programNational ResearchNational Tumor Biology Laboratory proiect
6 · The paper itself

Abstract

contextDNA demethylation and inhibitory effects of aspirin on pituitary cell proliferation have been demonstrated.

objectiveOur aim was to clarify the molecular mechanisms behind the aspirin-related effects in pituitary cells.

methodsDNA methylome and whole transcriptome profile were investigated in RC-4B/C and GH3 pituitary cell lines upon aspirin treatment. Effects of aspirin and a demethylation agent, decitabine, were further tested in vitro. PTTG1 expression in 41 human PitNET samples and whole genome gene and protein expression data of 76 PitNET and 34 control samples (available in Gene Expression Omnibus) were evaluated.

resultsAspirin induced global DNA demethylation and consequential transcriptome changes. Overexpression of Tet enzymes and their cofactor Uhrf2 were identified behind the increase of 5-hydroxymethylcytosine (5hmC). Besides cell cycle, proliferation, and migration effects that were validated by functional experiments, aspirin increased Tp53 activity through p53 acetylation and decreased E2f1 activity. Among the p53 controlled genes, Pttg1 and its interacting partners were downregulated upon aspirin treatment by inhibiting Pttg1 promoter activity. 5hmC positively correlated with Tet1-3 and Tp53 expression, and negatively correlated with Pttg1 expression, which was reinforced by the effect of decitabine. Additionally, high overlap (20.15%) was found between aspirin-regulated genes and dysregulated genes in PitNET tissue samples.

conclusionA novel regulatory network has been revealed, in which aspirin regulated global demethylation, Tp53 activity, and Pttg1 expression along with decreased cell proliferation and migration. 5hmC, a novel tissue biomarker in PitNET, indicated aspirin antitumoral effect in vitro as well. Our findings suggest the potential beneficial effect of aspirin in PitNET.

Indexed as

AdenomaPituitary NeoplasmsAspirinDecitabineHumansMixed Function OxygenasesProto-Oncogene ProteinsSecurinTumor Suppressor Protein p53Ubiquitin-Protein LigasesAspirinDecitabineMixed Function Oxygenasespituitary tumor-transforming protein 1, humanProto-Oncogene ProteinsSecurinTET1 protein, humanTumor Suppressor Protein p53Ubiquitin-Protein LigasesUHRF2 protein, humanbiomarkerdemethylationepigeneticmethylationpitNETpituitarypituitary adenomapttg1

Identifiers

PMID36059148
PMCPMC9681612
OpenAlexW4294607498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.